Advertisement

European Journal of Clinical Pharmacology

, Volume 43, Issue 3, pp 295–297 | Cite as

Effect of age on the disposition of sodium fluoride

  • C. Jeandel
  • F. Lapicque
  • P. Netter
  • B. Bannwarth
  • C. Monot
  • P. Gillet
  • E. Payan
  • M. Guillaume
  • G. Cuny
Originals

Summary

Sodium fluoride (NaF) is used in the treatment of axial osteoporosis and so is mostly given to old patients. Since its pharmacokinetics has not been studied in the elderly, the pharmacokinetics of an enteric-coated tablet containing 50 mg NaF has been investigated in 15 aged inpatients (aged 65 to 75 y) and 12 young healthy volunteers (aged 21 to 26 y).

The serum AUC of fluoride was 1.7-time higher in older than in younger subjects. There was a strong inverse correlation between the AUC and either body surface area (BSA) or glomerular filtration rate (GFR), both of which were very much lower in the elderly.

This concluded that if efficacy or safety are related to the bioavailability of fluoride, it maybe valuable to adjust the dosage of fluoride accordingly to the GFR and BSA.

Key words

Sodium fluoride osteoporosis, single-dose pharmacokinetics, age 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rich C, Ensink J (1961) Effect of sodium fluoride on calcium metabolism of human beings. Nature 191: 184–185PubMedGoogle Scholar
  2. 2.
    Hodsman AB, Drost DJ (1989) The response of vertebral bone mineral density during the treatment of osteoporosis with sodium fluoride. J Clin Endocrinol Metab 69: 932–938PubMedGoogle Scholar
  3. 3.
    Ekstrand J, Alvan G, Boreus LO, Norlin A (1977) Pharmacokinetics of fluoride in man after single and multiple oral doses. Eur J Clin Pharmacol 12: 311–317CrossRefPubMedGoogle Scholar
  4. 4.
    Ekstrand J, Ehrnebo M, Boreus LO (1978) Fluoride bioavailability after intravenous and oral administration: importance of renal clearance and urine flow. Clin Pharmacol Ther 23: 329–337PubMedGoogle Scholar
  5. 5.
    Chaleil D, Mauras Y, Allain P (1986) Oral pharmacokinetics of an enteric-coated sodium fluoride preparation. Trace Elements Medicine 3: 11–13Google Scholar
  6. 6.
    Chaleil D, Boulard C, Guillaume M, Allain P (1988) Etude pharmacocinétique du fluorure après une administration unique d'Ostéofluor. Thérapie 43: 5–7PubMedGoogle Scholar
  7. 7.
    Briancon D, Quillet P, Duplan B, Chapuy MC, Arlot M, Meunier PJ (1988) Comparaison de la biodisponibilité du fluor à la suite de l'administration de fluorure de sodium seul ou en association avec du calcium. Thérapie 43: 107–110PubMedGoogle Scholar
  8. 8.
    Mamelle N, Meunier PJ, Dusan R, Guillaume M, Martin JL, Gaucher A, Prost A, Ziegler G, Netter P (1988) Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 2: 361–365PubMedGoogle Scholar
  9. 9.
    Riggs BL, Hodgson SF, O'Fallon WN, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton LJ (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 12: 802–809Google Scholar
  10. 10.
    Greenblatt DJ, Divol LM, Abernethy DR, Shader RI (1982) Physiologic changes in old age: relation to altered drug disposition. J Am Geriatr Soc 30: 6–10Google Scholar
  11. 11.
    Shand DG (1982) Biological determinants of altered pharmacokinetics in the elderly. Gerontology 28: 8–17PubMedGoogle Scholar
  12. 12.
    Greenblatt DJ, Sellers EM, Schader RI (1982) Drug therapy: drug disposition in old age. N Engl J Med 28: 8–17Google Scholar
  13. 13.
    Ekstrand J, Ericsson Y, Resell S (1977) Absence of protein bound fluoride from human blood plasma. Arch Oral Biol 22: 229–232PubMedGoogle Scholar
  14. 14.
    Whitford GM, Pashley DH, Stringer GI (1976) Fluoride renal clearance: a pH-dependent event. Am J Physiol 230: 527–532PubMedGoogle Scholar
  15. 15.
    Hosking DJ, Chamberlain MJ (1972) Studies in man with 18 F. Clin Sci 42: 153–161PubMedGoogle Scholar
  16. 16.
    Spencer H, Kramer L, Osis D, Wiatrowski E (1975) Excretion of retained fluoride in man. J Appl Physiol 38: 282–287PubMedGoogle Scholar
  17. 17.
    Parsons V, Davies C, Ogg CS, Siddiquadi JY, Geode GC (1971) The ionic composition of bone from patients with chronic renal failure and on RDT with special reference to fluoride and aluminium. Proc Eur Dialysis Transplant Ass 8: 139–148Google Scholar
  18. 18.
    Parkins FM, Tinanoff N, Mouhinho M, Anstey MB, Waziri M (1974) Relationships of human plasma fluoride and bone fluoride to age. Calcif Tissue Res 16: 335–338CrossRefPubMedGoogle Scholar
  19. 19.
    Kuo HC, Stamm JW (1975) The relationship of creatinine clearance to serum fluoride concentration and urinary fluoride excretion in man. Arch Oral Biol 20: 235–238PubMedGoogle Scholar
  20. 20.
    Cowell DC, Taylor WH (1981) Ionic fluoride: a study of its physiological variation in man. Ann Clin Biochem 18: 76–83PubMedGoogle Scholar
  21. 21.
    Einwag J, Trautner K (1984) Fluoridkonzentration im Serum und Fluoridausscheidung im Urin nach oraler Aufnahme von 530 mg fluorid aus NaF-Lösung. Dtsch Zahnärztl Z 39: 699–704PubMedGoogle Scholar
  22. 22.
    Trautner K, Siebert G (1986) An experimental study of bioavailability of fluoride from dietary sources in man. Archs Oral Biol 31: 223–228CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • C. Jeandel
    • 1
    • 2
  • F. Lapicque
    • 1
  • P. Netter
    • 1
  • B. Bannwarth
    • 1
  • C. Monot
    • 1
  • P. Gillet
    • 1
  • E. Payan
    • 1
  • M. Guillaume
    • 3
  • G. Cuny
    • 2
  1. 1.Département de Pharmacologie Clinique, Faculté de MédecineURA CNRS 1288Vandoeuvre-les-NancyFrance
  2. 2.Service de Médecine Interne et GérontologieHôpital de BraboisNancy
  3. 3.Laboratoire Merck ClévenotNogent sur MarneFrance

Personalised recommendations